(BFRG)

NCM – Real Time Price. Currency in USD

0.51

-0.03 (-6.22%)

At close: Mar 27, 2026, 4:00 PM EDT

0.51

0.00 (0.00%)

After-hours: Mar 27, 2026, 7:59 PM EDT

About the company

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Key Executives

Name	Position
Dr. Cetin Savkli Ph.D.	Chief AI Advisor & Member of Advisory Board
Dr. David P. Recker FACP, FACR, M.D.	Chief Medical Officer
Dr. Praveen Kudithipudi M.B.A., M.D.	Chief Business Development Officer
Mr. Antonio V. Montano	Chief Marketing Officer & Growth Strategy Leader
Mr. J. T. Koffenberger	Chief Information Officer